Art. -Nr.: HY-N0370

Bergapten

Name: Bergapten
Brand: MedChemExpress
SKU: HY-N0370
Price: 85.00 USD
Availability: InStock
Rating: 5 (6 reviews)

(Synonyms: 5-Methoxypsoralen)

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

Bergapten is a natural anti-inflammatory and anti-tumor agent. Bergapten is inhibitory towards mouse and human CYP isoforms.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit : 99.85%
CAS. Nr.: 484-20-8
Formel: C₁₂H₈O₄
Molecular Weight:216.19

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Bergapten Chemical Structure

CAS. Nr.: 484-20-8

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Protokoll (1)
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Bergapten is a natural anti-inflammatory and anti-tumor agent. Bergapten is inhibitory towards mouse and human CYP isoforms.

IC₅₀ & Target

CYP^[1]

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>20 μg/mL Compound: 14	Cytotoxicity against human A549 cells by MTT assay Cytotoxicity against human A549 cells by MTT assay	[PMID: 29975532]
HeLa	IC₅₀	>20 μM Compound: 5-MOP	The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the dark	[PMID: 10543884]
HeLa	IC₅₀	16.3 μM Compound: 5-MOP	The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated) The compound was tested in vitro for growth inhibition against HeLa(human cervix adenocarcinoma) cell line in the presence of UVA(ultra violet A irradiated)	[PMID: 10543884]
Hepatocyte	IC₅₀	>100 μM Compound: 15	Inhibitory activity against D-GalN-induced cytotoxicity in rat hepatocytes Inhibitory activity against D-GalN-induced cytotoxicity in rat hepatocytes	[PMID: 9873511]
HepG2	IC₅₀	>20 μg/mL Compound: 14	Cytotoxicity against human HepG2 cells by MTT assay Cytotoxicity against human HepG2 cells by MTT assay	[PMID: 29975532]
HL-60	IC₅₀	>20 μM Compound: 5-MOP	The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the dark	[PMID: 10543884]
HL-60	IC₅₀	3.35 μM Compound: 5-MOP	The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated) The compound was tested in vitro for growth inhibition against HL-60(human promyelocytic leukemia) cell line in the presence of UVA(ultra violet A irradiated)	[PMID: 10543884]
HSC-2	CC₅₀	0.72 mM Compound: 24	Cytotoxicity against human HSC2 cells Cytotoxicity against human HSC2 cells	[PMID: 11170668]
HT-1080	IC₅₀	0.9 μM Compound: 5-MOP	Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 6.5 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
HT-1080	IC₅₀	1.8 μM Compound: 5-MOP	Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 3.2 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
HT-1080	IC₅₀	8.5 μM Compound: 5-MOP	Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line Inhibition of cell growth after irradiation at UVA dose of 2.6 J/cmE-2 in HT1080 human fibrosarcoma cell line	[PMID: 12873520]
L929	IC₅₀	101 μM Compound: 1, 5-MOP	Inhibition of Kv1.3 potassium channel expressed in mouse L929 cells by whole cell patch clamp Inhibition of Kv1.3 potassium channel expressed in mouse L929 cells by whole cell patch clamp	[PMID: 19056148]
MDA-MB-231	IC₅₀	>20 μg/mL Compound: 14	Cytotoxicity against human MDA-MB-231 cells by MTT assay Cytotoxicity against human MDA-MB-231 cells by MTT assay	[PMID: 29975532]

In Vitro

There is decreased N-acetyltransferase (NAT) activity in SC-M1 cells at concentrations of Bergapten (5-Methoxypsoralen, 5-MOP) from 0.05 mM to 25 mM, but no obvious dose-dependent effect is found between these doses (r=0.5687). In COLO 205 cells, there is decreased NAT activity at low doses of Bergapten (0.05 mM and 0.5 mM) and increased NAT activity at a high dose (50 mM). Bergapten induces a dosedependent effect in our experimental concentrations on COLO 205 cells (r=0.8912); a promotion effect at a higher dose (50 mM) and an inhibition effect at lower doses (0.05-0.5 mM), while the concentrations 5-25 mM has no significant difference compared with the control regimen^[1]. Bergapten (5-Methoxypsoralen) exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice. Bergapten has also been shown to significantly inhibit the production of pro-inflammatory cytokines. Bergapten exhibits the ability to significantly inhibit RANKL-RANK signaling transduction, and to suppress the activation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways, thus protecting trabecular structure and decreasing osteoclastogenic differentiation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

In Vivo

The metabolic activity of NAT of the rat colon is higher than that of the stomach, and Bergapten (5-Methoxypsoralen, 5-MOP) causes a decrease of AF concentration in the stomach at the 24-h time-period. The concentrations of AAF in the stomach and colon are low. Although DMSO (solvent) influenced the metabolism of AAF, compared with the control regimen, Bergapten still causes an increase in the further metabolism of AAF, and a decrease in the concentration of AAF in the stomach at 24 h, and in the colon during the 24- to 72-h time-period^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 484-20-8
Appearance Solid
Molecular Weight 216.19
Formel C₁₂H₈O₄
Color White to off-white
SMILES

O=C1C=CC2=C(OC)C3=C(OC=C3)C=C2O1
Synonyms

5-Methoxypsoralen
Structure Classification
- Phenylpropanoids
- Coumarins
Initial Source
- Plants
- other families
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (6)

All Cell Proliferation/Viability AssayFlow CytometryCell Migration/Invasion AssayCell Imaging/StainingWBRT-PCRELISA

Sort by:

Journal Impact Factor

Acta Pharmacol Sin

Bergapten inhibits NLRP3 inflammasome activation and pyroptosis via promoting mitophagy. [Abstract]

2023 Sep;44(9):1867-1878. PMID: 37142684

Bergapten purchased from MedChemExpress. Usage Cited in: Acta Pharmacol Sin. 2023 Sep;44(9):1867-1878. [Abstract]

Bergapten (BeG; 5, 10, 20 μM; 2 h) inhibits the expression of cleaved caspase-1 in BMDMs and J774A.1 cells.(5, 10 μM for J774A.1 cells, 20 μM for both)
PLoS Biol

A high-throughput behavioral screening platform for measuring chemotaxis by C. elegans. [Abstract]

2024 Jun 27;22(6):e3002672. PMID: 38935621
Eur J Pharmacol

Bergapten promotes angiogenesis by enhancing endothelial autophagy and reducing pyroptosis in ischemic skin flap. [Abstract]

2026 Jun 25:1030:179091. PMID: 42349817
Oncol Lett

Network pharmacology and molecular docking reveal the mechanism of action of Bergapten against non‑small cell lung cancer. [Abstract]

2024 Dec 4;29(2):87. PMID: 39677411

Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]

After 72 h of treatment with Bergapten (5-methoxypsoralen, 0-60 μM, 72 h), the viability of these cells was measured using the Cell Counting Kit-8 assay and the optimal drug concentration was determined.

Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]

Apoptosis levels was measured using flow cytometry after 72 h of treatment with Bergapten (5-methoxypsoralen, 30-50 μM, 72 h).

Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]

5-methoxypsoralen inhibits the migration of lung cancer cells. Representative images of wound healing assays using 40 or 50 µM Bergapten (5-methoxypsoralen) in NCI-H1299.

Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]

Representative images of NCI-H1975, NCI-H129 and NCI-H460 cells treated with 40 or 50 µM Bergapten (magnification, ×200).

Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]

Western blot analysis used to determine the expression of P-PI3K, PI3K, P-AKT and AKT proteins in three types of cells after treatment Bergapten.

Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]

RT-qPCR analysis determined the P16, P21, MMP12, IL6 and IL8 mRNA levels after treatment with Bergapten.

Bergapten purchased from MedChemExpress. Usage Cited in: Oncol Lett. 2024 Dec 4;29(2):87. [Abstract]

ELISA was used to detect the AKT activation levels of three cell lines after treatment with 5-methoxypsoralen, 5-methoxypsoralen + DMSO and Bergapten + SC79.
bioRxiv

An efficient behavioral screening platform classifies natural products and other chemical cues according to their chemosensory valence in C. elegans. [Abstract]

2024 Apr 3:2023.06.02.542933. PMID: 37333363
bioRxiv

2023 Jun 15.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 20 mg/mL (92.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

4.6256 mL

23.1278 mL

46.2556 mL

5 mM

0.9251 mL

4.6256 mL

9.2511 mL

10 mM

0.4626 mL

2.3128 mL

4.6256 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 1 mg/mL (4.63 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 1 mg/mL (4.63 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protokoll

All Signal Pathway Related

Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Lee YM, et al. Effects of 5-methoxypsoralen (5-MOP) on arylamine N-acetyltransferase activity in the stomach and colon of rats and human stomach and colon tumor cell lines. In Vivo. 2005 Nov-Dec;19(6):1061-9. [Content Brief]

[2]. Li XJ, et al. Bergapten exerts inhibitory effects on diabetes-related osteoporosis via the regulation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways in osteoprotegerin knockout mice. Int J Mol Med. 2016 Dec;38(6):1661-1672. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	4.6256 mL	23.1278 mL	46.2556 mL	115.6390 mL
	5 mM	0.9251 mL	4.6256 mL	9.2511 mL	23.1278 mL
	10 mM	0.4626 mL	2.3128 mL	4.6256 mL	11.5639 mL
	15 mM	0.3084 mL	1.5419 mL	3.0837 mL	7.7093 mL
	20 mM	0.2313 mL	1.1564 mL	2.3128 mL	5.7820 mL
	25 mM	0.1850 mL	0.9251 mL	1.8502 mL	4.6256 mL
	30 mM	0.1542 mL	0.7709 mL	1.5419 mL	3.8546 mL
	40 mM	0.1156 mL	0.5782 mL	1.1564 mL	2.8910 mL
	50 mM	0.0925 mL	0.4626 mL	0.9251 mL	2.3128 mL
	60 mM	0.0771 mL	0.3855 mL	0.7709 mL	1.9273 mL
	80 mM	0.0578 mL	0.2891 mL	0.5782 mL	1.4455 mL

Bioz

Keywords

Bergapten

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Bergapten

Publications Citing Use of MedChemExpress (MCE) Bergapten

Alle Cytochrome P450 Isoform-spezifische Produkte anzeigen